• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美国新冠突破性感染:对延长疫情的影响

Breakthrough COVID-19 Infections in the US: Implications for Prolonging the Pandemic.

作者信息

Alcendor Donald J, Matthews-Juarez Patricia, Smoot Duane, Hildreth James E K, Lamar Kimberly, Tabatabai Mohammad, Wilus Derek, Juarez Paul D

机构信息

Department of Microbiology, Immunology and Physiology, Center for AIDS Health Disparities Research, School of Medicine, Meharry Medical College, 1005 D.B. Todd Jr. Blvd., Nashville, TN 37208, USA.

Center for AIDS Health Disparities Research, Department of Microbiology, Immunology, and Physiology, School of Medicine, Meharry Medical College, 1005 D.B. Todd Jr. Blvd., Hubbard Hospital, 5th Floor, Rm. 5025, Nashville, TN 37208, USA.

出版信息

Vaccines (Basel). 2022 May 11;10(5):755. doi: 10.3390/vaccines10050755.

DOI:10.3390/vaccines10050755
PMID:35632512
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9146933/
Abstract

The incidence of COVID-19 breakthrough infections-an infection that occurs after you have been vaccinated-has increased in frequency since the Delta and now Omicron variants of the SARS-CoV-2 coronavirus have become the dominant strains transmitted in the United States (US). Evidence suggests that individuals with breakthrough infections, though rare and expected, may readily transmit COVID-19 to unvaccinated populations, posing a continuing threat to the unvaccinated. Here, we examine factors contributing to breakthrough infections including a poor immune response to the vaccines due to the fact of advanced age and underlying comorbidities, the natural waning of immune protection from the vaccines over time, and viral variants that escape existing immune protection from the vaccines. The rise in breakthrough infections in the US and how they contribute to new infections, specifically among the unvaccinated and individuals with compromised immune systems, will create the need for additional booster vaccinations or development of modified vaccines that directly target current variants circulating among the general population. The need to expedite vaccination among the more than 49.8 million unvaccinated eligible people in the US is critical.

摘要

自新冠病毒(SARS-CoV-2)的德尔塔毒株,以及现在的奥密克戎毒株成为美国主要传播毒株以来,新冠病毒突破性感染(即在接种疫苗后发生的感染)的发生率不断上升。有证据表明,突破性感染的个体虽然罕见但也在意料之中,他们可能会轻易地将新冠病毒传播给未接种疫苗的人群,对未接种疫苗者构成持续威胁。在此,我们研究了导致突破性感染的因素,包括由于高龄和潜在合并症对疫苗免疫反应不佳、疫苗免疫保护随时间自然减弱,以及逃避现有疫苗免疫保护的病毒变体。美国突破性感染的增加及其如何导致新的感染,特别是在未接种疫苗者和免疫系统受损个体中的感染,将产生对额外加强疫苗接种或开发直接针对普通人群中当前流行变体的改良疫苗的需求。加快美国4980多万符合条件但未接种疫苗人群的疫苗接种至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9034/9146933/8ce3c29a8220/vaccines-10-00755-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9034/9146933/29f8703b0a11/vaccines-10-00755-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9034/9146933/1d539b1278cc/vaccines-10-00755-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9034/9146933/1cbe17908fc4/vaccines-10-00755-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9034/9146933/0a3437e4dc31/vaccines-10-00755-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9034/9146933/8ce3c29a8220/vaccines-10-00755-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9034/9146933/29f8703b0a11/vaccines-10-00755-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9034/9146933/1d539b1278cc/vaccines-10-00755-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9034/9146933/1cbe17908fc4/vaccines-10-00755-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9034/9146933/0a3437e4dc31/vaccines-10-00755-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9034/9146933/8ce3c29a8220/vaccines-10-00755-g005.jpg

相似文献

1
Breakthrough COVID-19 Infections in the US: Implications for Prolonging the Pandemic.美国新冠突破性感染:对延长疫情的影响
Vaccines (Basel). 2022 May 11;10(5):755. doi: 10.3390/vaccines10050755.
2
Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland-A multicentre cohort study.瑞士一项多中心队列研究:根据德尔塔和奥密克戎变异株流行期间的基线免疫状态和加强针接种情况,评估卫生专业人员感染 COVID-19 的风险和症状。
PLoS Med. 2022 Nov 7;19(11):e1004125. doi: 10.1371/journal.pmed.1004125. eCollection 2022 Nov.
3
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study.比较分析英国住院和死亡风险与 SARS-CoV-2 奥密克戎(B.1.1.529)和德尔塔(B.1.617.2)变异株的关系:一项队列研究。
Lancet. 2022 Apr 2;399(10332):1303-1312. doi: 10.1016/S0140-6736(22)00462-7. Epub 2022 Mar 16.
4
Molecular and Clinical Epidemiology of SARS-CoV-2 Infection among Vaccinated and Unvaccinated Individuals in a Large Healthcare Organization from New Jersey.新泽西州一家大型医疗机构中接种和未接种人群中 SARS-CoV-2 感染的分子和临床流行病学研究。
Viruses. 2023 Aug 5;15(8):1699. doi: 10.3390/v15081699.
5
A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.一种基于三聚体 RBD 的马赛克型 COVID-19 疫苗候选物可诱导针对奥密克戎和其他 SARS-CoV-2 变体的强大中和作用。
Elife. 2022 Aug 25;11:e78633. doi: 10.7554/eLife.78633.
6
A Quick Displacement of the SARS-CoV-2 variant Delta with Omicron: Unprecedented Spike in COVID-19 Cases Associated with Fewer Admissions and Comparable Upper Respiratory Viral Loads.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变异株德尔塔迅速被奥密克戎取代:新冠病毒疾病病例数出现前所未有的激增,住院人数减少,上呼吸道病毒载量相当。
medRxiv. 2022 Jan 28:2022.01.26.22269927. doi: 10.1101/2022.01.26.22269927.
7
Likelihood of infecting or getting infected with COVID-19 as a function of vaccination status, as investigated with a stochastic model for Aotearoa New Zealand for Delta and Omicron variants.作为奥克兰新新西兰的德尔塔和奥密克戎变体的随机模型调查,接种疫苗状态对感染或感染 COVID-19 的可能性的影响。
N Z Med J. 2022 Apr 1;135:89-100.
8
Infection-mediated immune response in SARS-CoV-2 breakthrough infection and implications for next-generation COVID-19 vaccine development.SARS-CoV-2 突破感染中的感染介导免疫反应及其对下一代 COVID-19 疫苗开发的影响。
Vaccine. 2024 Feb 27;42(6):1401-1406. doi: 10.1016/j.vaccine.2024.01.088. Epub 2024 Feb 2.
9
Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers.与未接种疫苗的患者相比,使用主要生物标志物比较感染 SARS-CoV-2 Delta 或 Omicron VOC 患者的疾病严重程度和同源疫苗接种效果。
J Med Virol. 2022 Dec;94(12):5867-5876. doi: 10.1002/jmv.28098. Epub 2022 Sep 9.
10
Shift in SARS-CoV-2 variants of concern from Delta to Omicron was associated with reduced hospitalizations, increased risk of breakthrough infections but lesser disease severity.从德尔塔变异株到奥密克戎变异株的转变与住院人数减少、突破性感染风险增加有关,但疾病严重程度较低。
J Infect Public Health. 2024 Jun;17(6):1100-1107. doi: 10.1016/j.jiph.2024.04.025. Epub 2024 May 3.

引用本文的文献

1
Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in People Living with HIV (PLWH).单价奥密克戎XBB.1.5适应性BNT162b2新冠疫苗在艾滋病毒感染者(PLWH)中的免疫原性。
Vaccines (Basel). 2024 Jul 17;12(7):785. doi: 10.3390/vaccines12070785.
2
SARS-CoV-2 ORF3a Protein as a Therapeutic Target against COVID-19 and Long-Term Post-Infection Effects.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的ORF3a蛋白作为抗2019冠状病毒病(COVID-19)及感染后长期影响的治疗靶点
Pathogens. 2024 Jan 14;13(1):75. doi: 10.3390/pathogens13010075.
3
Risks of Adverse Outcomes for Hospitalized COVID-19 Patients during the Four Waves in Brazil According to SARS-CoV-2 Variants, Age Group, and Vaccine Status.

本文引用的文献

1
Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant.德尔塔刺突 P681R 突变增强了 SARS-CoV-2 对阿尔法变体的适应能力。
Cell Rep. 2022 May 17;39(7):110829. doi: 10.1016/j.celrep.2022.110829. Epub 2022 Apr 29.
2
Risk of Vaccine Breakthrough SARS-CoV-2 Infection and Associated Factors in Healthcare Workers of Trieste Teaching Hospitals (North-Eastern Italy).的里雅斯特教学医院(意大利东北部)医护人员中新冠病毒疫苗突破性感染的风险及相关因素
Viruses. 2022 Feb 7;14(2):336. doi: 10.3390/v14020336.
3
Influence of the Delta Variant and Vaccination on the SARS-CoV-2 Viral Load.
巴西 COVID-19 住院患者在四波疫情期间根据 SARS-CoV-2 变异株、年龄组和疫苗接种状况出现不良结局的风险。
Viruses. 2023 Sep 26;15(10):1997. doi: 10.3390/v15101997.
4
Assessment of Immunogenicity and Efficacy of CV0501 mRNA-Based Omicron COVID-19 Vaccination in Small Animal Models.基于CV0501 mRNA的奥密克戎新冠疫苗在小动物模型中的免疫原性和有效性评估
Vaccines (Basel). 2023 Jan 31;11(2):318. doi: 10.3390/vaccines11020318.
5
Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses.重新思考针对冠状病毒、流感病毒和其他呼吸道病毒的下一代疫苗。
Cell Host Microbe. 2023 Jan 11;31(1):146-157. doi: 10.1016/j.chom.2022.11.016.
6
Risk factors for severe Covid-19 breakthrough infections: an observational longitudinal study.严重新冠突破性感染的风险因素:一项观察性纵向研究。
BMC Infect Dis. 2022 Nov 28;22(1):894. doi: 10.1186/s12879-022-07859-5.
7
The feasibility, safety, and efficacy of Paxlovid treatment in SARS-CoV-2-infected children aged 6-14 years: a cohort study.帕罗韦德治疗6至14岁新冠病毒感染儿童的可行性、安全性和有效性:一项队列研究
Ann Transl Med. 2022 Jun;10(11):619. doi: 10.21037/atm-22-2791.
德尔塔变异株和疫苗接种对 SARS-CoV-2 病毒载量的影响。
Viruses. 2022 Feb 4;14(2):323. doi: 10.3390/v14020323.
4
Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression.疫苗预防严重急性呼吸综合征冠状病毒 2 型(SARS-CoV-2)感染和 COVID-19 疾病有效性的持续时间:系统评价和荟萃回归的结果。
Lancet. 2022 Mar 5;399(10328):924-944. doi: 10.1016/S0140-6736(22)00152-0. Epub 2022 Feb 23.
5
Addressing Vaccine Inequity - Covid-19 Vaccines as a Global Public Good.应对疫苗不平等——将新冠疫苗视为全球公共产品
N Engl J Med. 2022 Mar 24;386(12):1176-1179. doi: 10.1056/NEJMe2202547. Epub 2022 Feb 23.
6
Genomic Surveillance for SARS-CoV-2 Variants: Predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) Variants - United States, June 2021-January 2022.SARS-CoV-2 变体的基因组监测:Delta(B.1.617.2)和奥密克戎(B.1.1.529)变体占主导地位-美国,2021 年 6 月-2022 年 1 月。
MMWR Morb Mortal Wkly Rep. 2022 Feb 11;71(6):206-211. doi: 10.15585/mmwr.mm7106a4.
7
Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies.奥密克戎:一种高度突变的 SARS-CoV-2 变体,表现出对 ACE2 更强的结合能力,并能有效逃避已批准的 COVID-19 治疗性抗体。
Front Immunol. 2022 Jan 24;12:830527. doi: 10.3389/fimmu.2021.830527. eCollection 2021.
8
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.严重急性呼吸综合征冠状病毒2型奥密克戎变异株B.1.1.529可导致广泛的中和抗体反应逃逸。
Cell. 2022 Feb 3;185(3):467-484.e15. doi: 10.1016/j.cell.2021.12.046. Epub 2022 Jan 4.
9
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies.一种传染性 SARS-CoV-2 B.1.1.529 奥密克戎病毒能够逃避治疗性单克隆抗体的中和作用。
Nat Med. 2022 Mar;28(3):490-495. doi: 10.1038/s41591-021-01678-y. Epub 2022 Jan 19.
10
The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic.奥密克戎变异株对抗体介导的中和作用具有高度抗性:对控制 COVID-19 大流行的影响。
Cell. 2022 Feb 3;185(3):447-456.e11. doi: 10.1016/j.cell.2021.12.032. Epub 2021 Dec 24.